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Abstract 
 
Context: 
Recessive mutations in TMEM38B cause type XIV osteogenesis imperfecta (OI) by 
dysregulating intracellular calcium flux.  
Objectives:  
Clinical and bone material phenotype description and osteoblast differentiation studies. 
Design and Setting:  
Natural history study in paediatric research centres. 
Patients:  
Eight patients with type XIV OI. 
Main Outcome Measures:  
Clinical examinations included: bone mineral density, radiographs, echocardiography and 
muscle biopsy. Bone biopsy samples (n=3) were analysed using histomorphometry, 
quantitative backscattered electron microscopy and Raman microspectroscopy. Cellular 
differentiation studies were performed on proband and control osteoblasts and normal 
murine osteoclasts. 
Results:  
The clinical phenotype of type XIV OI ranges from asymptomatic to severe. Previously 
unreported features include vertebral fractures, periosteal cloaking, coxa vara and 
extraskeletal features (muscular hypotonia, cardiac abnormalities). Proband L1-L4 bone 
density Z-score was reduced (median -3.3 [range -4.77 to +0.1; n=7]), and increased by 
+1.7 (1.17 to 3.0; n=3) following bisphosphonate therapy. TMEM38B mutant bone has 
reduced trabecular bone volume, osteoblast and particularly osteoclast numbers, with 
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>80% reduction in bone resorption. Bone matrix mineralization is normal and 
nanoporosity low. We demonstrate a complex osteoblast differentiation defect with 
decreased expression of early markers and increased late and mineralization-related 
markers. Predominance of TRIC-B over TRIC-A expression in murine osteoclasts 
supports an intrinsic osteoclast defect underlying low bone turnover. 
Conclusions:  
OI type XIV has a bone histology, matrix mineralization and osteoblast differentiation 
pattern that is distinct from OI with collagen defects. Probands are responsive to 
bisphosphonates and some show muscular and cardiovascular features possibly related to 
intracellular calcium flux abnormalities. 
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INTRODUCTION 
Osteogenesis Imperfecta (OI) is a clinically and genotypically heterogeneous, heritable 
connective tissue disorder which results in fragile, deformed bones, short stature and low 
bone mass (1). Most cases of OI are due to dominantly inherited mutations in COL1A1 or 
COL1A2 which affect the structure or quantity of type I collagen (Types I-IV) (2,3). Rare, 
mostly recessive, forms of OI are caused by defects in genes whose products are involved 
with collagen folding or post-translational modification (2,4-7).  
 
Recessively inherited mutations in the TMEM38B gene (OMIM#611236), which encodes the 
ubiquitously expressed ER protein Trimeric Intracellular Cation channel type B (TRIC-B), 
cause OI type XIV (OMIM #615066). TMEM38B mutations reported to date include an exon 
4 deletion among Bedouins (8,9), an exon 1-2 deletion in an Albanian child (10) and two 
point mutations in exon 4 and intron 3 in three Chinese children (11). Using primary 
fibroblasts and osteoblasts from affected individuals, we recently demonstrated that absence 
of TRIC-B disrupts ER calcium flux kinetics, consistent with increased activation of the 
PERK/ATF4 pathway of ER stress (12,13). Expression of multiple genes for collagen-
interacting proteins is altered in proband cells, leading to dysregulated type I collagen 
synthesis, including decreased hydroxylation of collagen helical lysine residues and 
intracellular retention of misfolded collagen (12). The full clinical and skeletal phenotype, 
bone histomorphometry, bone material properties, osteoblast differentiation pattern and 
response to bisphosphonate (BP) therapy have not previously been presented. 
 
MATERIAL AND METHODS 
Clinical Data, Samples and Bone Imaging 
Clinical information and anthropometric data were taken from medical records of six patients 
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(P1-6) with genetically confirmed type XIV OI attending OI specialist clinics at Birmingham 
Children’s Hospital, Birmingham, UK; two brothers (P7,8) were studied at the NIH Clinical 
Center, Bethesda, MD, USA. In both centers, all patients with clinical signs suggestive of OI 
are offered genetic testing using a recessive OI gene panel. Blood, bone biopsy and DNA 
samples were collected from the patients and their parents after obtaining informed 
consent/assent. Bone densitometry, including lateral vertebral assessment (Hologic or GE 
Lunar iDXA™), and X-rays were taken as part of routine clinical care or OI natural history 
protocols. Lateral vertebral morphometry was assessed using the Genant score (14). 
 
Bone tissue characteristics: Bone Histomorphometry, quantitative Backscattered Electron 
Imaging (qBEI) and Raman Microspectroscopy 
Trans-iliac bone biopsies were taken in patients 2, 4 and 7 (when naïve to BP therapy) and 
repeated in P7 after one year of BP therapy. Double-labeling with tetracycline for dynamic 
measurement of bone formation was performed in P2 and P7. Sample preparation and 
histomorphometric analyses were performed using standard procedures (15). Bone 
mineralisation density distribution (BMDD), reflecting the calcium content of bone matrix, 
was measured in trabecular and cortical bone by qBEI as described previously (16).  
 
Raman microspectroscopy was used to evaluate the properties of the trabecular bone mineral 
and organic matrix as a function of 4 tissue ages (17,18): i) between the 2nd fluorescent label 
and the mineralizing front (1-3 day-old bone), ii) between the two fluorescent labels (4-20 
day-old bone), iii) immediately behind the 1st fluorescent label (over 20 day-old bone), and, 
iv) the geometrical centre of trabeculae (older bone tissue). At each tissue age, the 
mineral/matrix ratio, nanoporosity (a surrogate of tissue water), glycosaminoglycan, lipid and 
pyridinoline content were determined, as previously described (18). Results from bone 
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histomorphometry, qBEI and Raman analysis were compared to paediatric reference data 
from healthy subjects, and type I OI patients (17,19-23). 
 
Molecular Studies 
Genomic DNA was extracted using standard protocols. For P1-6, clonal sequencing using 
SureSelect target enrichment (Agilent Technologies) and the Illumina MiSeq platform was 
performed using a custom designed gene panel. Sequence analysis using a custom 
bioinformatics pipeline based on open source workflow by the Broad Institute 
(http://www.broadinstitute.org/gatk/guide/best-practices) was undertaken using a minimum 
threshold of 30-fold read depth for exonic sequence and intron/exon boundary. Variants 
identified were filtered against polymorphism lists and assessed using the Association for 
Clinical Genetic Science Best Practice Guidelines (http://www.acgs.uk.com). For P7 and P8, 
the maternal TMEM38B mutation was detected by NGS using a recessive OI panel (CTGT, 
Allentown, PA, USA). Subsequently, the paternal mutation was detected by deletion analysis 
(12). 
 
Cell Culture 
Primary osteoblast (OB) cultures were established from surgical bone chips of normal control 
(aged 4 years) and P7 (prepubertal, aged 13 years), as previously described (24). To induce 
OB differentiation, confluent cells were cultured for 30 days in MEM, supplemented with 
10% fetal bovine serum, 1% pen-strep, 25 μg/mL L-ascorbic acid, 10−8 M dexamethasone 
and 2.5 mM 2-glycerophosphate.  
Bone marrow-derived primary osteoclast (OC) cultures were generated from femora of 8-
week BL/6 mice as previously described (25). Cultures were assessed for an OC phenotype 
by the presence of multinucleated TRACP-positive stained cells (Sigma). 
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Analysis of Gene Expression 
Total RNA was extracted from patient OB and mouse OC cultures at the indicated time 
points using TriReagent (Molecular Research Center) according to the manufacturer’s 
protocol, then treated with DNA-free (Life Technologies). Gene transcript levels of cell 
differentiation markers were quantitated by real-time RT-PCR following reverse-
transcription using a High Capacity cDNA Archive Kit and Taqman Assays on Demand 
(Suppl. Information 1). Relative expression of genes of interest was measured in triplicate 
and normalized to 2 reference genes (ACTB, B2M, Actb, and B2m).  
 
RESULTS 
Molecular Studies 
P1-6 originated from three apparently unrelated Pakistani families living in Birmingham, UK, 
and presented with increased bone fragility and osteoporosis. Sanger sequencing confirmed 
that all probands were homozygous for the same c.507G>A mutation in exon 4 of 
TMEM38B. This mutation replaces tryptophan169 with a STOP codon (p.W169X). All 
obligate carrier parents were heterozygous for the mutation (Suppl. Figure 1). 
 
P7 and P8 were born to unrelated American parents of British/Scottish and British/German 
origin and found to be compound heterozygous for the previously reported deletion 
encompassing TMEM38B exons 1 and 2 (10) and a novel c.63dupT, which directly 
introduces a premature termination codon (p.D22X). Their father carries the deletion and 
their mother the c.63dupT allele.  
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Both genotypes lead to a TMEM38B null molecular outcome in fibroblast and OB cultures of 
patients P2 and P7 (who appear as Probands 3 and 2 respectively, in (12)). 
 
Clinical and Radiological Phenotype  
Expressivity of clinical OI features was highly variable (Table 1). P1 and P6 presented 
antenatally with bowed femora. P1-7 had sustained a significant low trauma fracture by 2 
years of age, whilst P8 had no fractures. Two individuals were short (height < -2 SDs) and 
overweight. P5 had non-progressive bilateral nephrocalcinosis of unknown origin detected at 
birth. P7 has relative macrocephaly (58cm, 98th centile) with normal brain MRI, facial 
appearance and dentition. His clinical OI phenotype was severe whilst his brother (P8) was 
asymptomatic, indicating incomplete penetrance. All had normal calcium and phosphate 
metabolism, only P2 had consistently elevated alkaline phosphatase (ALP) levels. 
 
Cognitive Development 
P1 and P2 developed motor skills appropriately but have delayed speech and language 
development. P2 has a concomitant diagnosis of autistic spectrum disorder. Cognitive 
development is normal in P3-8. 
 
Radiological Findings 
Long bone radiographs of all patients demonstrated osteopenia (Suppl. Figure 2). Five 
patients required femoral rodding (Table 1). Interestingly, P1 whose radiographs at birth 
showed femoral bowing with mid-shaft cortical thickening, developed widespread periosteal 
reactions (‘cloaking’) of all long bones at 2 months of age. A follow-up skeletal survey at 22 
months of age showed resolving periosteal reaction, coxa vara and osteopenia (Suppl. Figure 
2 A-C, E, F, H, I). In contrast, P7 has extremely thin long bones (Suppl. Figure 2 N, O). P1 
had 4-5 Wormian bones around the lambdoid suture at age 2 months.  
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Spine and Respiratory 
P1 had multiple vertebral compression fractures at age 2 months which showed incomplete 
reshaping by 22 months (Suppl. Figure 2 A, D, G). P2 had multiple vertebral compression 
fractures at presentation aged 12 years (Suppl. Figure 2 J). To date, two patients (25%) have 
developed scoliosis (Cobb angle >10˚), which is progressively deforming in P5 and P7. 
Following spinal rodding surgery at age 15 years, P5 has severe restrictive lung disease. P7 
developed moderate lower airway obstruction with air trapping at age 22 years (Table 1). 
 
Cardiovascular Health 
Three patients (P3,5,7) displayed cardiac pathology. P3 presented aged 14 years with 
secondary amenorrhea, significant weight gain (BMI 32kg/m2) and hirsutism. She had 
impaired glucose tolerance (120 min glucose 10.4mmol/L post oral glucose load), acanthosis 
nigricans, and fatty liver on ultrasound. She was started on metformin and later on a 
combined ethinylestradiol/cyproterone acetate contraceptive pill (COCP), on which her 
hirsutism, weight gain and periods improved. Aged 16 years, she had an extensive anterior 
myocardial infarction secondary to a thrombus in the left anterior descending coronary artery. 
Her COCP was discontinued. P5 had a large congenital secundum atrial septal defect and a 
perimembraneous ventricular septal defect. He developed heart failure, requiring surgery 
aged 2 months. P7’s echocardiogram aged 21 years revealed tricuspid regurgitation with an 
anatomically normal valve. At age 27, asymmetric septal hypertrophy of the left ventricle and 
mild aortic root dilation were detected. The septal hypertrophy progressed further and he 
developed non-obstructive hypertrophic cardiomyopathy with ST elevation and borderline 
right axis deviation on ECG. Cardiovascular lipid profile was normal in all eight individuals. 
Echocardiogram and ECG were normal in P1,2,4-6,8. 
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Muscle Phenotype 
P1-3 and P6, their unaffected siblings, and P7 and P8 have no evidence of myopathy. P4 has 
muscular hypotonia, which was fully investigated. Her EMG showed a denervating pattern 
with no suggestion of muscle myopathic activity. Muscle biopsy also showed no evidence of 
congenital myopathy, metabolic or storage disorder or mitochondrial cytopathy. Serum 
lactate, basic mitochondrial DNA screen and MRI brain were normal. She walks with a 
Trendelenburg gait. Her brother, P5, also has moderate hypotonia associated with delayed 
motor milestones, and only walked without support at 3 years of age.  
 
Clinical and radiological phenotype of heterozygous carriers 
Parents of affected patients had no history of fractures, were generally healthy, with normal 
lumbar spine bone density (BMD) where measured (Z-scores: 0.7 to -0.3, n=4). Parents of 
P7/8 were fully assessed. Their father, age 59 years, has macrocephaly (59cm, >95th centile), 
moderate hip laxity, degenerative changes in mid-thoracic vertebrae, normal BMD (Z-score 
+0.1), and occupational high-frequency hearing loss bilaterally. Echocardiogram shows 
concentric left ventricular hypertrophy, mildly dilated ascending aorta, and mild mitral and 
aortic regurgitation with normal valvular anatomy. Their mother, age 56 years, has type I DM 
and Graves’ Disease, short stature and normal head circumference. Radiographs show mild 
central compressions of lower thoracic and lumbar vertebrae, with normal BMD (Z-score -
0.3). Calcifications were noted in the abdominal aorta on X-rays, with annular calcification of 
mitral and aortic valves. She has mild mid-frequency sensorineural hearing loss bilaterally. 
 
Bone mineral density and response to BP treatment 
Proband lumbar spine BMD Z-scores varied widely, ranging from normal (P3,4) to 
osteopenic (P6,8) to decreased (P2,5,7) with mean median Z-score -3.3 [range -4.77 to  
+0.1]) in individuals old enough to be measured (P2-8, Table 2). Four patients were 
 11 
treated with BPs. DXA scans before and after treatment (n=3) revealed substantial 
increase in BMD Z-score of 3, 1.7 and 1.17 SD (median +1.7), respectively. Patients with 
BMD Z-scores within the normal range have not required BP treatment to date. 
 
Evaluation of trans-iliac bone biopsies 
A) Bone histomorphometry (Table 3) 
The main histomorphometric features in the trans-iliac biopsy samples (P2,4,7) were 
predominance of low BV/TV, normal to reduced OB numbers and very low resorption. 
Backscattered electron images demonstrate bone volumes (BV/TV) below -1SD in P4 
(Figure 1C) and below -4SD (-82% from normal) in P7 (Figure 1D).  Whilst BV/TV could 
not be assessed in P2, many thin and partially isolated trabecular features were viewed in the 
cancellous compartment (Figure 1A, B). Trabecular surfaces (in P2 and P7) were covered by 
an abnormally extended and thin osteoid layer resulting in a substantial increase in osteoid 
surface (OS/BS) and osteoid volume (OV/BV) (Table 3). Unlike OI caused by collagen-gene 
mutations, neither OB nor OC indices were increased in affected patients. In fact, OB surface 
(Ob.S/BS) and mineralizing surface (MS/BS) were within normal range or decreased (P4). 
Interestingly, despite the low amount of trabecular bone, intense fluorescent double labels 
were detected in cortical bone (Figure 1E, P7). P2 had focal areas of osteoid accumulation 
which explains the elevated mineralization lag time (Mlt) and the low adjusted apposition 
rate (aj.AR). In all patients, OC and bone resorption indices were markedly decreased to less 
than 20% of healthy controls. Bone cortex had a normal thickness, lamellar pattern, and 
normal haversian canals.  
 
B) qBEI (Table 4) 
Trabecular bone: 
In P2 and P7, the average bone matrix mineralization was normal, rather than elevated as in 
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OI type I bone. The matrix portion with low mineralization (CaLow) was slightly above both 
the healthy reference and OI type I ranges. In contrast, P4 had a BMDD curve that was 
shifted towards higher matrix mineralization (Figure 1F) with increased CaMean, CaPeak 
and CaHigh values, consistent with low turnover revealed on histomorphometry. In all 
patients, the portion of fully mineralized CaHigh was markedly lower (53-84%) than in OI 
type I.  
Cortical bone: 
The CaMean and CaPeak of P2 and P4 were within the normal range, although again P4 
showed increased CaHigh. In contrast, P7’s cortical bone matrix before BP treatment was 
much less mineralized than control bone, even less than his trabecular bone (CaMean: -7%, 
and -10% respectively). Concomitantly, there was a 3-fold increase of CaLow reflecting the 
large portion of bone undergoing primary mineralization. The high cortical bone apposition 
was mirrored by strong tetracycline labeling on endo –and intracortical surfaces (Figure 1E). 
After one year of BP therapy, P7’s cortical CaMean and CaPeak increased and CaLow 
decreased substantially, reflecting increasing tissue age due to the anticatabolic therapy.  
 
C) Raman Microspectroscopy 
Mineral/matrix and mineral maturity/crystallinity ratios were within reference range of 
healthy children. Nanoporosity was decreased (at younger tissue ages in P2, P7 and oldest in 
P4), compared to healthy controls and even lower than classical OI bone. Relative 
glycosaminoglycan content at the oldest tissue age was decreased in P2,4 and increased in P7 
compared to healthy children. Lipid content was lower in P2 and P7 compared to healthy 
children. Finally, pyridinoline content was comparable to OI type I bone, being higher than 
normal at the two younger tissue ages, and normal at older ones (Suppl. Table 1). 
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Osteoblast and osteoclast studies 
Cultured osteoblasts from P7 showed reduced expression of early markers of differentiation 
(RUNX2, SP7, COL1A1, SPARC), an increase in later markers, including those related to 
mineralization (ALPL, OPN, IBSP, BGLAP, DMP) and also delayed SOST expression 
(Figure 2). The normal RANKL/OPG profile suggests normal functioning of the major 
extrinsic OC stimulation system. To explain the low bone resorption on patient bone 
histomorphometry, we examined osteoclasts from murine cultures, since cultures of patient 
osteoclasts were not available. We determined whether Tric-b and its coupled [Ca2+] channel 
Itpr3 were expressed in differentiated murine osteoclasts, as well as the potential for 
redundancy by Tric-a and its coupled Ryr3 [Ca2+] channel in this cell type (26). The results 
confirm marked predominant expression of the ER TRIC-B channel over TRIC-A (10-15-
fold in mature OC), and the IP3R3 [Ca
2+] efflux channel over RyR3 ( 25-fold), respectively 
(Figure 2, bottom panels). 
 
DISCUSSION 
TMEM38B null mutations cause type XIV OI by disturbing ER calcium flux kinetics, which 
alters the function of multiple proteins in the ER (12). Type I collagen post-translational 
modification displays a distinct pattern, with decreased helical and increased telopeptide lysyl 
hydroxylation, which contrasts with the helical over-modification typical of classical 
dominant OI and recessive defects in procollagen prolyl 3-hydroxylation. Procollagen in 
TMEM38B-null cells is also misfolded and substantially degraded intracellularly, underlying 
reduced collagen secretion (12). Here, we present our extensive investigations of the type 
XIV OI phenotype, its distinctive bone tissue characteristics and bone cellular defects. 
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The skeletal phenotype of our eight patients had variable expressivity and penetrance, 
ranging from barely detectable to severe. Development of scoliosis and hearing loss was also 
variable. We observed previously unreported features such as vertebral fractures with 
spontaneous reshaping, periosteal cloaking, coxa vara and abnormal dentition. Periosteal 
cloaking similar to our observation in P1 appears present on radiographs of other patients 
with OI type XIV (8) and OI of unknown etiology (27). Such generalised cloaking may 
represent a response to healing long bone fractures and is not typical of classical OI. Cardiac 
abnormalities of different etiologies were observed in three patients, and in both carrier 
parents of P7/8. P4 and P5 have muscular hypotonia. However, muscle and myocardial cells 
express much more TRIC-A than the ubiquitous TRIC-B (28), although TRIC-B deficiency 
may indirectly affect these tissues via increased ER stress. Tric-a and Tric-b double KO mice 
die in-utero due to cardiac arrest, indicating a shared role of these channels in Ca2+ signalling 
in embryonic cardiomyocytes. In addition, even Tric-b+/- mice are susceptible to stress-
induced heart failure (28), which potentially indicates an association between the cardiac 
findings and the heterozygous state of P7/8’s parents. Until more evidence becomes 
available, monitoring cardiovascular risk factors in affected patients may be required. In 
addition, the lack of significant respiratory abnormalities in our patients contrasts with the 
Tric-b KO mouse model, which shows respiratory defects with abnormal IP3R-mediated Ca
2+ 
release in airway epithelial cells. Finally, in view of parental consanguinity, we cannot 
confidently attribute cognitive impairment in P1 and P2 to a TMEM38B effect in 
neuroepithelial tissue.  
 
OI type XIV bone is structurally distinct from bone with type I collagen gene defects. In the 
absence of TRIC-B, bone tissue has low-normal OB numbers with a low mineral apposition 
rate (Aj.AR) and a uniform paucity of OCs. In classical OI, bone turnover and cell numbers 
 15 
are high, but mineral apposition rate is low, implying that many OBs produce less matrix, 
which is typically hypermineralized (23,29). BMDD by qBEI in TRIC-B deficient bone is 
either normal or slightly right-shifted, reflecting a situation of low bone turnover that allows 
more time for bone packets to mineralize (16,30). Specifically P4 has a high mineralization, 
low turnover profile similar to children with chronic kidney disease or slow growth (31). In 
contrast, bone from P7, with the most severe skeletal phenotype, featured active OBs on 
rudimental trabeculae, a lack of OCs but normal BMDD. Strikingly, his cortex showed active 
primary bone formation as evidenced by intense intra- and endocortical fluorescence labeling 
(Figure 2E) and increased cortical CaLow. Raman microspectroscopy also revealed an 
unaltered mineral/matrix ratio in TMEM38B mutant bone. However, similar to classical OI 
bone, nanoporosity, a surrogate of tissue water, was decreased at the three younger tissue 
ages compared to healthy controls (22). Consistently, elevated pyridinoline content at the two 
younger tissue ages mirrors increased or accelerated trivalent cross-links formation resulting 
in stiffer collagen fibers, which exhibit more “brittle-like” behavior (32). Thus, bone fragility 
in type XIV OI is explained by reduced trabecular bone and nanoporosity, and increased 
pyridinoline content. Despite low bone resorption, bone mineral density and cortical mineral 
content increased in response to BP therapy in Type XIV OI patients. The observed shift 
towards higher, and less heterogeneous, cortical BMDD following one year of BP therapy is 
characteristic for patients with normal or lowered mineralization density (16). This contrasts 
sharply to classical OI bone where the hypermineralized, fully saturated matrix cannot further 
increase its density (29).  
 
Differentiation of P7’s osteoblasts demonstrated reduced expression of early markers of 
differentiation (RUNX2, SP7, and COL1A1), which is consistent with reduced OB numbers 
shown on bone biopsy, and would exacerbate the decreased collagen secretion resulting from 
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collagen misfolding in the ER (12). Expression of the OB differentiation marker ALP is 
related to [Ca2+] flux since its suppression by siRNA blocks BMP2-induced flux of [Ca2+] 
from ER to cytoplasm, raising the proposal of ALP as a monitor of intracellular calcium 
concentration (33). Our cell culture work suggests that this loop may also work in the reverse 
direction, with reduced ER [Ca2+] flux in TRIC-B deficient cells leading to a compensatory 
increase in osteoblast ALPL expression.  
Calcium signalling has broad effects on pathways promoting and inhibiting mineralization. 
Expression of multiple genes whose products interact with [Ca2+] and/or influence 
mineralization are altered in Type XIV OI osteoblasts, although mineralization of type XIV 
OI bone tissue is not abnormal. Whilst expression of pro-mineralization ALP/ALPL (34) is 
increased, there is decreased expression of osteonectin/SPARC, which initiates and promotes 
mineralization, and increased expression of osteocalcin/BGLAP and OPN, which inhibit 
crystal growth (35,36). The SIBLING proteins BSP and OPN have generally opposing roles 
in promoting and opposing mineralization (37), but their concurrent increase in transcripts in 
TRIC-B deficient cells is unexpected, since BSP-/- cells have increased OPN expression (38). 
Further, SOST expression was delayed, suggesting differentiation to osteocytes may be 
impaired. The complex OB gene expression pattern apparently contravenes the usual OI 
mechanism toward hypermineralization. Studies on the levels and interactions of these 
proteins in TRIC-B deficient cells and matrix should be a focus of further investigation. In 
partial agreement with our patient findings, differentiated calvarial OBs of Tric-b KO mice 
have normal levels of type I collagen transcripts, with decreased collagen production due to 
intracellular degradation (26). As in patient cells, the early differentiation markers Runx2 and 
Osx are reduced in murine OBs. However, Alpl, Bsp and Bglap transcripts are reduced, while 
Sparc is normal, suggesting greater impairment of murine OB differentiation and 
mineralization than in patients. 
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An apparent intrinsic defect in osteoclasts is another distinctive feature of Type XIV OI. To 
investigate the low OC numbers and activity in patient bone in the context of normal 
osteoblast RANKL/OPG ratios, we investigated the levels of expression of the TRIC-B/IP3R 
and TRIC-A/RyR paired sets of channels for K+ entry and Ca2+ efflux from the ER in normal 
murine OCs. Our demonstration of 15-fold higher expression of TRIC-B relative to TRIC-A, 
and 25-fold higher expression of IP3R than RyR channels support the predominance of the 
TRIC-B system in osteoclasts, with minimal to no redundancy of function. Combined with 
patient histomorphometry and in vitro OB expression profiles, our data support an intrinsic, 
OB-independent, OC defect in patients with TMEM38B mutations. We speculate that 
interference with [Ca2+] flux kinetics in TRIC-B null OCs impairs their response to normal 
developmental signals, resulting in low OC numbers, and reduced bone resorption. In recent 
experimental data from Tric-b-/- mice (26), OC markers such as cathepsin K and Atp6v0d2 
had reduced expression in newborn murine femora.  
 
In conclusion, we describe a wide phenotypic spectrum of OI caused by TMEM38B 
mutations, ranging from asymptomatic to severe and novel skeletal and potential 
extraskeletal features. Such phenotypic variability even with identical genotypes may reflect 
different ethnic and genetic backgrounds, modifiers of TMEM38B expression or other genes 
involved in post-translational modification and ER calcium flux. Whilst the small number of 
biopsies with great variability limits interpretation, bone turnover and BMDD were 
remarkably lower than in classical OI (23). Although normal BMDD has also been reported 
in OI caused by WNT1 mutations (39), WNT1-deficient patients lack the abnormalities of 
type I collagen post-translational modification found in OI type XIV. The paucity of OBs and 
OCs, the normal BMDD with extremely reduced nanoporosity are uniquely different from 
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classical OI. Here, we further delineate the mechanism of bone fragility in TMEM38B mutant 
bone not only as a complex OB differentiation defect due to impaired ER Ca2+ flux kinetics, 
but also likely as an intrinsic OC defect. Despite the low bone resorption, patients still 
respond to BP therapy with increased BMD and cortical bone matrix mineralization. The role 
of TRIC-B in human OB and OC function, as well as cardiovascular or muscular health 
requires further study. 
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Figure Legends: 
Figure 1: Bone tissue characteristics 
Trans-iliac bone biopsy section of P2 under light microscopy (A) shows plump osteoblasts 
forming an unmineralized matrix (dark gray). Mineralized matrix appears light gray 
(Goldner’s trichrome staining represents originally mineralized bone matrix in green, and 
osteoid in purple). Active bone formation was very rarely sighted. Backscattered images 
show bone biopsy samples from P2 (B), P4 (C) and P7 (D). The very low amount of 
trabecular bone tissue in P7’s sample is consistent with his severe skeletal phenotype. Under 
confocal laser-scanning microscopy, fluorescent double labels are detected on intra- and 
endocortical bone surfaces (E, see white arrows), which does not reflect high bone 
remodeling but cortical bone apposition. F) BMDD curves of cancellous bone of the 3 
patients in relation to pediatric reference values (20) and to patients with OI type I (23). Note 
that P4 has very low bone turnover and consequently the BMDD curve was right-shifted, 
reflecting higher average tissue age of the bone packets. 
 
Figure 2: Proband (P7) osteoblast time curve versus controls, and murine osteoclast 
differentiation 
Osteoblast differentiation time course (from P7) depicting relative levels of RNA transcripts 
for various proteins involved in collagen synthesis or bone mineralisation, measured at 
baseline and every 5d, for 30d. RNA transcripts included RUNX2, SP7, COL1A1, ALPL 
(TNSALP), BGLAP (osteocalcin), SPARC (osteonectin), OPN (osteopontin), IBSP, DMP1, 
SOST and RANKL/OPG. Murine osteoclast differentiation cultures (bottom panels) were used 
to measure calcium channel expressions. Itpr3/Ryr3 transcripts are equivalent to those for the 
human ER calcium efflux channels IP3R and RyR, and Tric-b/Tric-a transcripts are 
equivalent to those for the human channels TRIC-B and TRIC-A. 
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Table 1 Clinical phenotype of affected patients 
 
Patient P1 P2 P3 P4 P5 P6 P7 P8  
Sex Male Male Female Female Male Female Male Male 
Antenatal Scan Bowed left 
femur 
Normal Normal Normal Normal Bowed 
femora 
Normal Normal 
Birth weight (kg) at term 2.5 2.7 2.4 2.9 1.8 2.3 3.4 2.64 (34 wks) 
Sclera Grey White White Blue White Blue Blue White 
Age 1st fracture (years) 0.2 2 2 0.3 0.5 0 0 No fractures 
Location 1st recorded 
fracture  
Vertebra Femur Femur Femur Tibia Femur Femur No fractures 
Rodding surgery location 
(age-years; number of 
operations) 
Femur (2.5;1) Femur 
(6.9;1) 
None Femur (2.5; 
1) 
Femur (7;1) 
Spine (12; 2) 
None Both Femora 
& right tibia 
(2-7; 7) 
None 
Developmental delay Global Global None None Motor Motor None None 
Hearing loss Sensorineural Normal Normal Normal Normal Normal Sensorineural Normal 
Scoliosis (Cobb  angle˚) None None None Minimal (4˚) Moderate 
(50˚) 
None Moderate 
(29˚) 
Minimal (2˚) 
Height Z-score (age, years) -1.07 (4) 0.2 (14.11) -1.9 (22) -2 (22) -1.27 (14.6) -1.2 (11.9) -3 (27) 0.1 (24) 
Weight Z-score (age, years) 1.48 (4) 2.6 (14.11) 1.5 (22) 1 (22) 0.01 (14.6) -0.2 (11.9) 0 (27) 1.5 (24) 
BMI Z-score 3.07 2.4 1.9 1.7 0.76 0.6 (11.9) 1 1.5 
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Table 2 Bone density, fractures and response to bisphosphonate therapy 
 
* lumbar spine QCT density Z-score -2.9; ** age refers to earliest detection in patients with fractures, and latest assessment for those 
with none 
 
Patient P1 P2 P3 P4 P5 P6 P7 P8 
Current age (years) 4 15 26 24 14.9 12 27 24 
Lumbar spine BMD Z-score (age 
in years) 
Too young -3.1 (12) -0.5 (23) 0.1 (21) -2.0 (4) -1.6 (5) -4.77 (12) * -1.8 (24) 
Lumbar spine BMD Z-score post-
BP treatment (duration in years) 
N/A -0.1 (2) N/A N/A -0.3 (6) N/A -3.6 (1) N/A 
BP therapy Pamidronate, 
Zoledronate  
Zoledronate None None Pamidronate, 
Zoledronate  
None Pamidronate None 
Age started (years) 2 12 N/A N/A 5 N/A 13 N/A 
Number of vertebral fractures 
(age, years)** 
8 (0.2) 13 (11) None (24) None (21) 3 (4) None (12) None (27) None (24) 
Number of non-vertebral fractures 
prior to BP treatment (location) 
None 4 (femur) 2 (femur, 
radius) 
 
5 (femur) 
 
5 (tibia, 
femur, 
humerus) 
2 (femur, 
tibia) 
 
17 (lower 
extremity 
long bones) 
None 
Number of non-vertebral fractures 
after BPs started (location) 
2 (femur, tibia) 0 N/A N/A 1 (tibia) N/A 1 (tibia) N/A 
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Table 3 Results of bone histomorphometry 
 
 
 
For comparison, typical values for patients with OI type I are given (19). # Mean value from 
two cortical plates; ## sample contained only one cortical plate. Therefore, BV/TV and Tb.N 
could not be assessed. Patient 4 did not receive tetracycline labeling. 
Parameters  
Control values 
(15)  
Patient  
2 
Patient 
4 
Patient 
7 
OI type I  
(19) 
Age at biopsy 
(years) 
11-13.9 12  12  13  7.6 ± 3.8  
Structural parameters 
BV/TV [%]  24.4 ± 4.3 ## 17.98 4.46 11.0 ± 5.2 
Tb.Th [μm] 148 ± 23 93.43 141.64 53.94 105.0 ± 25 
Tb.N. [/mm] 1.66 ± 0.22 ## 1.27 0.83 1.3 ± 0.39 
Ct. Wi [mm] 0.90 ± 0.33 # 0.81## 0.60 0.56 0.52 ± 0.20 
Static parameters of bone formation 
OV/BV  [%] 2.12 ± 1.0 4.18 1.97 4.73 5.2 ± 2.6 
O.Th [µm] 6.7 ± 1.7 4.55 7.94 3.43 5.5 ± 1.7 
OS/BS [%] 22.1 ± 7.8 54.22 17.23 38.08 48 ± 14 
ObS/BS [%] 6.7 ± 4.5 2.97 0.96 8.98 19.4 ± 9.5 
Dynamic parameters of bone formation 
MS/BS [%] 11.07 ± 5.0 7.05 n.a 9.93 48 ± 16 
MAR [µm/d] 0.87 ±0.09 0.92 n.a 0.77 0.73 ± 0.18 
Aj. AR [µm/d] 0.46 ± 0.10 0.12 n.a 0.20 0.35 ± 0.14 
BFR/BS [µm/y] 37.3 ± 16.7 23.77 n.a 27.75 77 ± 34 
BFR/BV [%/y] 49.9 ± 21.4 50.28 n.a 108.18 116 ± 62  
Mlt  [d] 14.5 ± 3.00 37.88 n.a 17.18 
16.5  
[12.5 -19.8] 
Static parameters of bone resorption 
ES/BS [%] 14.9 ± 5.6 2.94 1.55 0 
15.6  
[13.7 - 21.8] 
Oc.S/BS [%] 1.14 ± 0.74 0.15 0.10 0 
1.37   
[1.05 - 1.70] 
N. Oc/BS [/mm] 0.29 ± 0.14 0.04 0.03 0 0.47 ± 0.29 
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Table 4 qBEI results from cancellous and cortical bone 
 
 
BMDD 
parameters: 
Reference values 
Controls (20) 
P2 P4* P7 # 
P7 post BP 
treatment 
Reference values 
OI type I (23) 
Cancellous bone 
CaMean 
[wt% Ca] 
20.95 
(0.57) 
20.67 22.09 21.10 - 
22.43 
(0.63) 
CaPeak 
[wt% Ca] 
21.66 
(0.52) 
21.66 22.87 22.36 - 
23.39 
(0.57) 
CaWidth 
[Δwt% Ca] 
3.47 
[3.12; 3.64] 
3.64 3.12 2.95 - 
3.08 
(0.28) 
CaLow 
[%] 
6.14 
[4.90; 7.99] 
9.65 4.43 9.59 - 
5.94 
(2.05) 
CaHigh 
[%] 
0.89 
[0.43; 1.47] 
1.24 3.54 2.03 - 
7.54 
[5.00;11.82] 
Cortical Bone 
CaMean 
[wt% Ca] 
20.45 
[19.68; 21.04] 
20.99 21.07 19.04 21.00 
22.51 
(0.46) 
(0.46) 
 
CaPeak 
[wt% Ca] 
21.14 
[20.62; 21.75] 
21.66 21.92 19.50 21.49 
23.29 
(0.48) 
- CaWidth 
[Δwt% Ca] 
3.81 
[3.38; 4.38] 
 
 
[3.38; 4.38] 
3.29 4.42 5.03 3.81 
3.28 
(0.25) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CaLow 
[%] 
9.06 
[6.22; 15.00] 
6.53 8.61 27.40 5.32 
4.60 
(0.80) 
- CaHigh 
[%] 
0.46 
[0.28; 1.22] 
0.81 2.33 0.36 0.44 
8.60 
(4.00) 
  
BMDD reference values for healthy controls (1.5 to 23 years) and OI patients (2 to 14 
years) are provided as median [interquartile range] or mean (SD), as appropriate 
(20,23). Note that the BMDD in healthy children has only minor variation and does not 
show any age-dependency (20) 
*Only one cortex available  
# High cortical bone formation 
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